Hodgkin's Disease Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Conditions:   Hodgkin Lymphoma;   Relapsed Hodgkin's Disease, Adult;   Refractory Hodgkin Lymphoma Interventions:   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2021 Category: Research Source Type: clinical trials